216 related articles for article (PubMed ID: 18236139)
1. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
5. Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
Haberer LJ; McSherry I; Cargill A; McCarthy L
Eur J Clin Pharmacol; 2014 Jan; 70(1):37-45. PubMed ID: 24100471
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
7. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
8. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
9. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
10. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
Kitamura S; Maeda K; Wang Y; Sugiyama Y
Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
[TBL] [Abstract][Full Text] [Related]
11. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
[TBL] [Abstract][Full Text] [Related]
12. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
13. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
[TBL] [Abstract][Full Text] [Related]
14. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
15. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH
Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565
[TBL] [Abstract][Full Text] [Related]
16. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
17. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
Sui SM; Wen JH; Li XH; Xiong YQ
Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531
[TBL] [Abstract][Full Text] [Related]
18. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
Tomita Y; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
[TBL] [Abstract][Full Text] [Related]
19. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
Hobbs M; Parker C; Birch H; Kenworthy K
Xenobiotica; 2012 Apr; 42(4):327-38. PubMed ID: 22035568
[TBL] [Abstract][Full Text] [Related]
20. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
Hua WJ; Hua WX; Fang HJ
Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
